Gabriel Chodick1,2, Lilac Tene1, Ran S Rotem1,3, Tal Patalon1, Sivan Gazit1, Amir Ben-Tov1,2, Clara Weil1, Inbal Goldshtein1,2, Gilad Twig2,4,5,6, Dani Cohen2, Khitam Muhsen2. 1. Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel. 2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. 4. Israel Defense Forces Medical Corps, Ramat-Gan, Israel. 5. Department of Military Medicine, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. 6. Institute of Endocrinology, Sheba Medical Center, Ramat-Gan, Israel.
Abstract
BACKGROUND: Coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines were shown to be highly efficacious in preventing the disease in randomized controlled trials; nonetheless, evidence on the real-world effectiveness of this vaccine is limited. Study objective was to evaluate the effectiveness of BNT162b2 vaccine in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19-related hospitalization and mortality. METHODS: This historical cohort study included members of a large health provider in Israel that were vaccinated with at least 1 dose of BNT162b2. The primary outcome was incidence rate of a SARS-CoV-2 infection confirmed with real-time polymerase chain reaction (rt-PCR), between 7 and 27 days after second dose (protection-period), as compared to days 1-7 after the first dose, where no protection by the vaccine is assumed (reference-period). RESULTS: Data of 1 178 597 individuals vaccinated with BNT162b2 were analyzed (mean age 47.7 years [SD = 18.1], 48.4% males) of whom 872 454 (74.0%) reached the protection period. Overall, 4514 infections occurred during the reference period compared to 728 during the protection period, yielding a weighted mean daily incidence of 54.8 per 100 000 (95% confidence interval [CI]: 26.1-115.0 per 100 000) and 5.4 per 100 000 (95% CI: 3.5-8.4 per 100 000), respectively. The vaccine effectiveness in preventing infection was 90% (95% CI: 79%-95%) and 94% (95% CI: 88%-97%) against COVID-19. Among immunosuppressed patients, vaccine effectiveness against infection was 71% (95% CI: 37%-87%). The adjusted hazard ratios for hospitalization in those infected were 0.82 (95% CI: .36-1.88), 0.45 (95% CI: .23-.90), and 0.56 (95% CI: .36-.89) in the age groups 16-44, 45-64. and ≥75 years, respectively. CONCLUSIONS: The effectiveness of the BNT162b2 vaccine is comparable to the one reported in the phase III clinical trial.
BACKGROUND: Coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines were shown to be highly efficacious in preventing the disease in randomized controlled trials; nonetheless, evidence on the real-world effectiveness of this vaccine is limited. Study objective was to evaluate the effectiveness of BNT162b2 vaccine in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19-related hospitalization and mortality. METHODS: This historical cohort study included members of a large health provider in Israel that were vaccinated with at least 1 dose of BNT162b2. The primary outcome was incidence rate of a SARS-CoV-2 infection confirmed with real-time polymerase chain reaction (rt-PCR), between 7 and 27 days after second dose (protection-period), as compared to days 1-7 after the first dose, where no protection by the vaccine is assumed (reference-period). RESULTS: Data of 1 178 597 individuals vaccinated with BNT162b2 were analyzed (mean age 47.7 years [SD = 18.1], 48.4% males) of whom 872 454 (74.0%) reached the protection period. Overall, 4514 infections occurred during the reference period compared to 728 during the protection period, yielding a weighted mean daily incidence of 54.8 per 100 000 (95% confidence interval [CI]: 26.1-115.0 per 100 000) and 5.4 per 100 000 (95% CI: 3.5-8.4 per 100 000), respectively. The vaccine effectiveness in preventing infection was 90% (95% CI: 79%-95%) and 94% (95% CI: 88%-97%) against COVID-19. Among immunosuppressed patients, vaccine effectiveness against infection was 71% (95% CI: 37%-87%). The adjusted hazard ratios for hospitalization in those infected were 0.82 (95% CI: .36-1.88), 0.45 (95% CI: .23-.90), and 0.56 (95% CI: .36-.89) in the age groups 16-44, 45-64. and ≥75 years, respectively. CONCLUSIONS: The effectiveness of the BNT162b2 vaccine is comparable to the one reported in the phase III clinical trial.
Authors: Ralf Duerr; Dacia Dimartino; Christian Marier; Paul Zappile; Guiqing Wang; Jennifer Lighter; Brian Elbel; Andrea B Troxel; Adriana Heguy Journal: J Clin Invest Date: 2021-09-15 Impact factor: 14.808
Authors: Nathaniel M Lewis; Eric A Naioti; Wesley H Self; Adit A Ginde; David J Douin; H Keipp Talbot; Jonathan D Casey; Nicholas M Mohr; Anne Zepeski; Manjusha Gaglani; Shekhar A Ghamande; Tresa A McNeal; Nathan I Shapiro; Kevin W Gibbs; D Clark Files; David N Hager; Arber Shehu; Matthew E Prekker; Heidi L Erickson; Michelle N Gong; Amira Mohamed; Daniel J Henning; Jay S Steingrub; Ithan D Peltan; Samuel M Brown; Emily T Martin; Kinsley Hubel; Catherine L Hough; Laurence W Busse; Caitlin C Ten Lohuis; Abhijit Duggal; Jennifer G Wilson; Alexandra J Gordon; Nida Qadir; Steven Y Chang; Christopher Mallow; Carolina Rivas; Hilary M Babcock; Jennie H Kwon; Matthew C Exline; Natasha Halasa; James D Chappell; Adam S Lauring; Carlos G Grijalva; Todd W Rice; Jillian P Rhoads; William B Stubblefield; Adrienne Baughman; Kelsey N Womack; Christopher J Lindsell; Kimberly W Hart; Yuwei Zhu; Stephanie J Schrag; Miwako Kobayashi; Jennifer R Verani; Manish M Patel; Mark W Tenforde Journal: J Infect Dis Date: 2022-05-16 Impact factor: 7.759
Authors: Tal Patalon; Sivan Gazit; Virginia E Pitzer; Ottavia Prunas; Joshua L Warren; Daniel M Weinberger Journal: JAMA Intern Med Date: 2022-02-01 Impact factor: 44.409
Authors: Cristina Bergamaschi; Evangelos Terpos; Margherita Rosati; Matthew Angel; Jenifer Bear; Dimitris Stellas; Sevasti Karaliota; Filia Apostolakou; Tina Bagratuni; Dimitris Patseas; Sentiljana Gumeni; Ioannis P Trougakos; Meletios A Dimopoulos; Barbara K Felber; George N Pavlakis Journal: Cell Rep Date: 2021-07-23 Impact factor: 9.423